Get the Stockscreener App
3.15
2.48%
-0.08
Lipocine Inc stock is traded at $3.15, with a volume of 21,567.
It is down -2.48% in the last 24 hours and down -1.25% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$3.23
Open:
$3.2924
24h Volume:
21,567
Relative Volume:
0.43
Market Cap:
$16.85M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-1.0328
EPS:
-3.05
Net Cash Flow:
$-11.88M
1W Performance:
-8.43%
1M Performance:
-1.25%
6M Performance:
-27.08%
1Y Performance:
-37.99%
1-Day Range:
$3.12
$3.2924
1-Week Range:
$3.12
$3.5288
52-Week Range:
$2.6838
$6.1683
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.15 | 17.28M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Pattern recognition hints at Lipocine Inc. upsideEquity Portfolio Outlook and Performance Summary - Newser
Using fundamentals and technicals on Lipocine Inc.Swing Watchlist With Tight Stop Placement - Newser
Historical volatility pattern of Lipocine Inc. visualizedSwing Trade Timing with Daily Forecast - Newser
Tools to assess Lipocine Inc.’s risk profileShort-Term Upside Breakout Forecast System - Newser
When is the best time to exit Lipocine Inc.Short-Term Support and Resistance Forecast - Newser
Is Lipocine Inc. a candidate for recovery playShort Term Gain Strategy with AI Logic - Newser
What are Lipocine Inc. company’s key revenue driversBreakout Stocks Tracker With High Returns - jammulinksnews.com
What makes Lipocine Inc. stock price move sharplyLow Risk Alerts Backed By Experts - jammulinksnews.com
Real time alert setup for Lipocine Inc. performanceMachine Learning Stock Movement Detector - Newser
Why is Lipocine Inc. stock attracting strong analyst attentionAdvanced Screener Data Feed To Watch Now - jammulinksnews.com
Is Lipocine Inc. reversing from oversold territorySwing Trade Signal and Price Prediction - Newser
Does Lipocine Inc. stock perform well during market downturnsBeginner Investor Planner With High Returns - jammulinksnews.com
Using flow based indicators on Lipocine Inc.Real Time Trade Execution Alert Plan - Newser
Candlestick signals on Lipocine Inc. stock todayLong-Term Signal Tracking and Profit Summary - Newser
Momentum Indicator Shows Bearish Divergence in Lipocine Inc.AI Forecast for Trending Stocks Indicates Upside - metal.it
Lipocine Inc. Recovers — But Is It SustainableOptimized Watchlist With Daily Adjustments Launched - metal.it
Price Consolidation Hints at Upcoming Move in Lipocine Inc.Multi-Bagger Potential Stock Forecast Tools Released - beatles.ru
RSI + MACD Show Convergence for Lipocine Inc.AI Screening for Swing Trade Picks Finds Momentum - metal.it
Chartists See Breakout Potential in Lipocine Inc.Verified Signal From Chart Patterns Detected - metal.it
How strong is Lipocine Inc. company’s balance sheetFree Risk Assessment Services - jammulinksnews.com
What institutional investors are buying Lipocine Inc. stockBuild a diversified portfolio for risk management - jammulinksnews.com
Is Lipocine Inc. stock overvalued or undervaluedSuperior investment outcomes - jammulinksnews.com
What is Lipocine Inc. company’s growth strategyConsistently superior profits - jammulinksnews.com
What are the latest earnings results for Lipocine Inc.Skyrocketing investment returns - jammulinksnews.com
How volatile is Lipocine Inc. stock compared to the marketMarket-leading growth rates - jammulinksnews.com
When is Lipocine Inc. stock expected to show significant growthAccelerated wealth building - jammulinksnews.com
Should I hold or sell Lipocine Inc. stock in 2025Stay ahead with advanced stock screening tools - jammulinksnews.com
How Resilient Is Lipocine Inc. Stock During Economic DownturnsSafe High Return Entry Points - metal.it
Lipocine Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingFree AI-Powered Stock Predictions - Newser
Intrinsic Value of Lipocine Inc. Stock: Is It Undervalued or Overvalued3x Return Stock Radar - Newser
Moving Average Trends for Lipocine Inc. Stock: What They IndicateLow Risk Stock Strategies - Newser
How Lipocine Inc. stock performs during market volatilityFree VIP Group - Newser
What analysts say about Lipocine Inc. stockHigh-impact stock picks - PrintWeekIndia
What drives Lipocine Inc. stock priceUnstoppable investment returns - Autocar Professional
Is Lipocine Inc. a good long term investmentFree Wealth Planning Blueprint - Autocar Professional
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):